Without full placebo data, it is hard to handicap VRDN-001’s chances in thyroid eye disease.
Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.
Key catalysts lie ahead for Amgen, Argenx, Point Biopharma and Novo Nordisk.
Several big groups’ portfolios are ageing, and regulatory action risks blocking their renewal.
Retatrutide looks like the most powerful obesity agent yet, though side effects will need careful monitoring.
The anti-Ox40 ligand antibody amlitelimab could have its work cut out to best the company’s own Dupixent.
Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.